MZT Matritech,

Matritech (Amex: MZT) today announced that it agreed with the holders of more than 90% of the outstanding principal value of its Series A 15% Secured Convertible Promissory Notes to defer these holders� receipt of principal and interest payments scheduled for April 13, 2007 to May 13, 2007. Matritech expects to make the payments on May 13, 2007 in shares of its common stock, consistent with its past practice. About Matritech Matritech, a leading marketer and developer of protein-based diagnostic products for the early detection of cancer, is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company�s first two products, the NMP22� Test Kit and NMP22� BladderChek� Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22� BladderChek� Test is based on Matritech�s proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech�s patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22� Test Kit and NMP22� BladderChek� Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company�s goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com. Statement under the Private Securities Litigation Reform Act Any forward-looking statements in this press release, including those related to the Company�s expectations regarding the form of payment of installments on its outstanding debt and its future compliance with applicable stock payment conditions, are subject to a number of risks and uncertainties, many of which are beyond the Company�s control. Please refer to the risk factors detailed in the Company�s periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company will be able to make future debt payments in shares of its common stock. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.